Rallybio agrees to reverse merger with Candid; Rallybio holders get ~3.65% of combined firm

Rallybio Corp

Rallybio pre-merger holders expected to own ~3.65% of combined company; Candid holders ~57.55%; financing investors ~38.80% (based on $505.5M raise).
Concurrent $505.5M private placement from accredited investors, shares convert to Rallybio common at closing.
Post-merger CEO will be Ken Song, current Candid Chairman/President/CEO; current Rallybio executives to resign.
Rallybio regained Nasdaq $1.00 bid compliance after 1-for-8 reverse stock split effective Feb 6, 2026.
Rallybio stockholders must approve share issuance (>20%), reverse split, name change to 'Candid Therapeutics, Inc.'

item 1.01 item 3.02 item 5.01 item 5.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Rallybio Corp entered into Agreement and Plan of Merger and Reorganization with Candid Therapeutics, Inc. (effective 2026-03-01).

Action: entry
Agreement: merger
Counterparty: Candid Therapeutics, Inc.
Effective: 2026-03-01

Exact text from the filing

On March 1, 2026, Rallybio Corporation, a Delaware corporation (“ Rallybio ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with Candid Therapeutics, Inc., a Delaware corporation (“ Candid ”)

View on SEC.gov

291 material agreements filed in the last 30 days. Browse all material agreements →

Rallybio Corp filing history →

Source: SEC EDGAR

accession 0001193125-26-084444

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.